Collectively, these findings suggest that the administration of BDNF gene-modified MSCs is insufficient, and further studies to determine the optimal strategies regarding the route, timing, and dose are warranted for their best therapeutic efficacy against severe neonatal HI brain injury [21]. This evidence concerns the gene BDNF and injury.